<DOC>
	<DOCNO>NCT00996931</DOCNO>
	<brief_summary>The purpose study determine lenalidomide ( Revlimid® ) reduce proinflammatory cytokine include TNF-alpha may actually alter clinical course autism child .</brief_summary>
	<brief_title>Efficacy Safety Lenalidomide Treatment Autistic Spectrum Disorders</brief_title>
	<detailed_description>Autism currently affect 1:142 birth definite cause . Recent research show possible identify marker neuroglial inflammation elevate cytokine IL-1 , Il-6 , MCP-1 elevate ratio CSF/serum level TNF-alpha patient regressive autism . Lenalidomide ( Revlimid® ) analogue thalidomide . Based improved clinical efficacy predict Revlimid® effect TNF-alpha immunomodulatory cytokine , oral compound may prove efficacious less toxicity compare thalidomide . The study evaluate efficacy lenalidomide measurement change EEG , clinical global impression , Childhood Autism Rating Scale , serum CSF ( available ) TNF-alpha end study compare measurement baseline .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis autistic spectrum disorder define DSMIV criterion . Inflammatory CSF serum marker elevate level TNFAlfa ( &gt; 50pg/ml ) Cytokine marker IL1 , IL6 MECP1 , serum level cytokines great 2X normal level even absence CSF marker . Patients interictal epiliptiform EEG change absences clinical seizure , CSF inflammatory marker identify . Patients maintain baseline medication autistic problem EEG treatment long prior 68 week dosage change . Mentally impaired minor require parent legal guardian sign inform consent . Diagnosis PPDNOS autism spectrum disorder . Any serious medical condition , laboratory abnormality , genetic , brain , structural , psychiatric illness would prevent subject participate . History neutropenia , thrombocytopenia type myelosuppression risk factor myelosuppression . History risk factor thromboembolic event . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . Use experimental drug therapy within 28 day baseline . Current use steroid ( e.g . dexamethasone , prednisone ) , anthracyclines ( Doxil , Adriamycin ) . Known hypersensitivity thalidomide . The development erythema nodosum characterize desquamate rash take thalidomide similar drug . Any prior use lenalidomide . Known positive HIV infectious hepatitis , type A , B C tuberculosis .</criteria>
	<gender>Male</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>autistic spectrum disorder</keyword>
	<keyword>lenalidomide</keyword>
</DOC>